Physician profile
Darrell S Surratt
NPI 1972570943
$8,432.44
in general payments reported to CMS, 2019-2025
50 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $1,256 · 2021: $1,866 · 2022: $1,351 · 2023: $1,193 · 2024: $979 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,146 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.25 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,625.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $775.20 | 2020-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $621.67 | 2019-2025 | |
| Astellas Pharma US INC | $525.16 | 2019-2023 | Veozah |
| Almatica Pharma LLC | $513.56 | 2021-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Lilly USA, LLC | $438.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $391.95 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $361.73 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.60 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $304.32 | 2022-2025 | |
| Glaxosmithkline, LLC. | $302.63 | 2020-2024 | Trelegy Ellipta |
| Allergan, INC. | $257.17 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $213.19 | 2020-2025 | Zoryve, Seglentis, Livalo |
| Amgen INC. | $172.78 | 2019-2024 | Otezla, Repatha |
| Antares Pharma, INC. | $142.56 | 2024-2025 | Xyosted |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Surratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.